RACE for Children Act | Pediatric Oncology Subcommittee
Executive Director Jonathan Agin Provides Public Comment Before the Food and Drug Administration On June 20, 2018, Executive Director Jonathan Agin provided open public comments before the Food and DrugThe Max Cure Foundation’s Aggressive Research Mission and Continued Legacy of Support for Memorial Sloan Kettering Cancer Center
The Max Cure Foundation’s Aggressive Research Mission and Continued Legacy of Support for Memorial Sloan Kettering Cancer Center Almost ten years ago, Max Plotkin sat anxiously in a small examResearch Update | Because of Daniel
One of the three pillars of Max Cure’s mission is funding research. Since our beginning, when Max was diagnosed in 2007 and fighting for his life, the understanding solidified thatChildhood Cancer, Noah’s Ark and My Daughter
Max Cure’s Executive Director Jonathan Agin is featured in Real Clear Health. “As the Executive Director of the Max Cure Foundation, I am no longer fighting for my daughter andApplying for Benefits for Pediatric Cancer
Applying for Benefits for Pediatric Cancer Introduction by Jonathan Agin, JD, Executive Director As a childhood cancer nonprofit organization, the Max Cure Foundation (MCF) continually engages in the fight against
pedODAC Meeting – DIPG
Jonathan Agin, JD, Executive Director’s Public Comments before the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (pedODAC) Meeting. On June 29, 2016, I was one of five individuals selected to
Max Cure Foundation’s 2015 Annual Appeal
You are brought into a small room: a doctor, a nurse, a social worker and you. The look on their faces is dire. You can feel the fear building; it
The End of Pediatric Cancer Research as We Know It? A commentary on Mathew Zachary’s piece and the Premature Argument that it is “Mission Accomplished”
Max Cure's Executive Director, Jonathan Agin provides commentary on Matthew Zachary's Piece and the Premature Argument that it is "Mission Accomplished."